Company · CIK 0001383701 · SIC 2834 — Pharmaceutical Preparations
Conatus Pharmaceuticals Inc. · CNAT
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| May 14, 2018 AForm 4 → | Feb 11, 2019, 4:20 pm EST | Edward F Smith IIISVP, Reg Affairs and QA | 6,414 | $3.27 | $20,955 | 10,875 | — | plan? late |
| May 14, 2018 AForm 4 → | Feb 11, 2019, 4:19 pm EST | Daniel L. RipleySVP, Bus Dev, P&A Mgmt | 3,151 | $3.22 | $10,132 | 32,431 | — | plan? late |
| May 4, 2018 MForm 4 → | May 7, 7:46 pm EDT | Steven J MentoPresident, CEO & Director, Director | 60,000 | $0.99 | $59,400 | 60,000 | — | plan? |
| Feb 27, 2018 MForm 4 → | Mar 1, 4:08 pm EST | Alfred P. SpadaEVP, R&D and CSO | 12,121 | $1.24 | $15,030 | 12,121 | — | plan? |
| Nov 14, 2017 AForm 4 → | Feb 5, 2018, 5:03 pm EST | Edward F Smith IIISVP, Reg Affairs and QA | 4,461 | $3.48 | $15,524 | 4,461 | — | plan? late |
| May 30, 2017 GForm 5 → | Feb 5, 2018, 5:05 pm EST | Michelle L VandertieVice President, Finance | 2,165 | — | — | 2,813 | — | plan? |
| May 12, 2017 AForm 4 → | Feb 5, 2018, 5:02 pm EST | Daniel L. RipleySVP, Bus Dev, P&A Mgmt | 1,579 | $2.62 | $4,140 | 29,280 | — | plan? late |
| Jan 9, 2017 MForm 4 → | Jan 11, 4:01 pm EST | Charles CashionSVP, Finance, CFO and Sec. | 42,424 | $0.99 | $42,000 | 42,424 | — | plan? |
| Dec 28, 2016 JForm 4 → | Dec 30, 5:24 pm EST | Daniel L KisnerDirector | 2,310 | — | — | 5,455 | — | plan? |
| Dec 20, 2016 MForm 4 → | Dec 22, 4:04 pm EST | Steven J MentoPresident, CEO & Director, Director | 41,414 | $1.21 | $50,091 | 41,414 | — | plan? |
| Oct 27, 2016 MForm 4 → | Oct 31, 4:37 pm EDT | Harold Van WartDirector | 18,181 | $0.25 | $4,545 | 18,181 | — | plan? |
| Apr 8, 2015 PForm 4 → | Apr 10, 4:02 pm EDT | Daniel L KisnerDirector | 4,000 | $5.75 | $23,000 | 7,145 | +127% | plan? |
| Apr 2, 2014 GForm 5 → | Feb 6, 2015, 4:04 pm EST | Charles CashionSVP, Finance, CFO and Sec. | 5,000 | — | — | 144,738 | — | plan? |
| Feb 19, 2014 JForm 4/A → | Dec 30, 2016, 5:22 pm EST | Daniel L KisnerDirector | 3,145 | — | — | 3,145 | — | plan? |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 7, 2019 AForm 4 → | Feb 11, 4:22 pm EST | Michelle L VandertieVice President, Finance | 50,000 | — | — | 50,000 | — | |
| Feb 7, 2019 AForm 4 → | Feb 11, 4:21 pm EST | Alfred P. SpadaEVP, R&D and CSO | 175,000 | — | — | 175,000 | — | |
| Feb 7, 2019 AForm 4 → | Feb 11, 4:20 pm EST | Edward F Smith IIISVP, Reg Affairs and QA | 100,000 | — | — | 100,000 | — | |
| Feb 7, 2019 AForm 4 → | Feb 11, 4:19 pm EST | Daniel L. RipleySVP, Bus Dev, P&A Mgmt | 100,000 | — | — | 100,000 | — | |
| Feb 7, 2019 AForm 4 → | Feb 11, 4:18 pm EST | Keith W MarshallEVP, COO & CFO | 175,000 | — | — | 175,000 | — | |
| Feb 7, 2019 AForm 4 → | Feb 11, 4:15 pm EST | David T HagertyEVP, Clinical Development | 175,000 | — | — | 175,000 | — | |
| Feb 7, 2019 AForm 4 → | Feb 11, 4:14 pm EST | Steven J MentoPresident, CEO & Director, Director | 350,000 | — | — | 350,000 | — | |
| Jun 21, 2018 AForm 4 → | Jun 25, 4:08 pm EDT | Harold Van WartDirector | 20,000 | — | — | 20,000 | — | |
| Jun 21, 2018 AForm 4 → | Jun 25, 4:07 pm EDT | James Paul ScopaDirector | 20,000 | — | — | 20,000 | — | |
| Jun 21, 2018 AForm 4 → | Jun 25, 4:07 pm EDT | William R LarueDirector | 20,000 | — | — | 20,000 | — | |
| Jun 21, 2018 AForm 4 → | Jun 25, 4:06 pm EDT | Preston KlassenDirector | 20,000 | — | — | 20,000 | — | |
| Jun 21, 2018 AForm 4 → | Jun 25, 4:05 pm EDT | Daniel L KisnerDirector | 20,000 | — | — | 20,000 | — | |
| Jun 21, 2018 AForm 4 → | Jun 25, 4:04 pm EDT | David F HaleDirector | 45,000 | — | — | 45,000 | — | |
| May 4, 2018 MForm 4 → | May 7, 7:46 pm EDT | Steven J MentoPresident, CEO & Director, Director | 60,000 | — | — | 147,070 | — | |
| Feb 27, 2018 MForm 4 → | Mar 1, 4:08 pm EST | Alfred P. SpadaEVP, R&D and CSO | 12,121 | — | — | 0 | — | |
| Feb 4, 2018 AForm 4 → | Feb 5, 5:04 pm EST | Michelle L VandertieVice President, Finance | 16,000 | — | — | 16,000 | — | |
| Feb 4, 2018 AForm 4 → | Feb 5, 5:03 pm EST | Alfred P. SpadaEVP, R&D and CSO | 70,000 | — | — | 70,000 | — | |
| Feb 4, 2018 AForm 4 → | Feb 5, 5:03 pm EST | Edward F Smith IIISVP, Reg Affairs and QA | 40,000 | — | — | 40,000 | — | |
| Feb 4, 2018 AForm 4 → | Feb 5, 5:02 pm EST | Daniel L. RipleySVP, Bus Dev, P&A Mgmt | 40,000 | — | — | 40,000 | — | |
| Feb 4, 2018 AForm 4 → | Feb 5, 5:00 pm EST | Keith W MarshallEVP, COO & CFO | 70,000 | — | — | 70,000 | — | |
| Feb 4, 2018 AForm 4 → | Feb 5, 4:59 pm EST | David T HagertyEVP, Clinical Development | 70,000 | — | — | 70,000 | — | |
| Feb 4, 2018 AForm 4 → | Feb 5, 4:57 pm EST | Steven J MentoPresident, CEO & Director, Director | 120,000 | — | — | 120,000 | — | |
| Aug 31, 2017 AForm 4 → | Sep 1, 4:14 pm EDT | Keith W MarshallEVP, COO & CFO | 525,000 | — | — | 525,000 | — | |
| Jun 22, 2017 AForm 4 → | Jun 26, 4:16 pm EDT | James Paul ScopaDirector | 20,000 | — | — | 20,000 | — | |
| Jun 22, 2017 AForm 4 → | Jun 26, 4:16 pm EDT | Preston KlassenDirector | 20,000 | — | — | 20,000 | — | |
| Jun 22, 2017 AForm 4 → | Jun 26, 4:15 pm EDT | Daniel L KisnerDirector | 20,000 | — | — | 20,000 | — | |
| Jun 22, 2017 AForm 4 → | Jun 26, 4:14 pm EDT | Harold Van WartDirector | 20,000 | — | — | 20,000 | — | |
| Jun 22, 2017 AForm 4 → | Jun 26, 4:12 pm EDT | David F HaleDirector | 45,000 | — | — | 45,000 | — | |
| Feb 6, 2017 AForm 4 → | Feb 7, 8:23 pm EST | William R LarueDirector | 30,000 | — | — | 30,000 | — | |
| Jan 26, 2017 AForm 4 → | Feb 2, 4:29 pm EST | Daniel L. RipleySVP, Bus Dev, P&A Mgmt | 73,000 | — | — | 73,000 | — | late |
| Jan 26, 2017 AForm 4 → | Feb 1, 4:25 pm EST | Alfred P. SpadaEVP, R&D and CSO | 100,625 | — | — | 100,625 | — | late |
| Jan 26, 2017 AForm 4 → | Feb 1, 4:23 pm EST | Edward F Smith IIISVP, Reg Affairs and QA | 57,500 | — | — | 57,500 | — | late |
| Jan 26, 2017 AForm 4 → | Feb 1, 4:22 pm EST | David T HagertyEVP, Clinical Development | 100,625 | — | — | 100,625 | — | late |
| Jan 26, 2017 AForm 4 → | Feb 1, 4:21 pm EST | Charles CashionSVP, Finance, CFO and Sec. | 57,500 | — | — | 57,500 | — | late |
| Jan 26, 2017 AForm 4 → | Feb 1, 4:20 pm EST | Steven J MentoPresident, CEO & Director, Director | 172,500 | — | — | 172,500 | — | late |
| Jan 9, 2017 MForm 4 → | Jan 11, 4:01 pm EST | Charles CashionSVP, Finance, CFO and Sec. | 42,424 | — | — | 0 | — | |
| Dec 20, 2016 MForm 4 → | Dec 22, 4:04 pm EST | Steven J MentoPresident, CEO & Director, Director | 41,414 | — | — | 207,070 | — | |
| Oct 27, 2016 MForm 4 → | Oct 31, 4:37 pm EDT | Harold Van WartDirector | 18,181 | — | — | 0 | — | |
| Jun 23, 2016 AForm 4 → | Jun 27, 4:23 pm EDT | Shahzad MalikDirector, 10% Owner | 20,000 | — | — | 20,000 | — | |
| Jun 23, 2016 AForm 4 → | Jun 24, 4:28 pm EDT | Harold Van WartDirector | 20,000 | — | — | 20,000 | — | |
| Jun 23, 2016 AForm 4 → | Jun 24, 4:26 pm EDT | James Paul ScopaDirector | 20,000 | — | — | 20,000 | — | |
| Jun 23, 2016 AForm 4 → | Jun 24, 4:21 pm EDT | Preston KlassenDirector | 20,000 | — | — | 20,000 | — | |
| Jun 23, 2016 AForm 4 → | Jun 24, 4:20 pm EDT | Daniel L KisnerDirector | 20,000 | — | — | 20,000 | — | |
| Jun 23, 2016 AForm 4 → | Jun 24, 4:18 pm EDT | David F HaleDirector | 45,000 | — | — | 45,000 | — | |
| Apr 1, 2016 AForm 4 → | Apr 4, 4:26 pm EDT | Edward F Smith IIISVP, Reg Affairs and QA | 100,000 | — | — | 100,000 | — | |
| Feb 4, 2016 AForm 4 → | Feb 8, 4:21 pm EST | Charles CashionSVP, Finance, CFO and Sec. | 62,500 | — | — | 12,500 | — | |
| Feb 4, 2016 AForm 4 → | Feb 8, 4:20 pm EST | David T HagertyEVP, Clinical Development | 131,250 | — | — | 21,875 | — | |
| Feb 4, 2016 AForm 4 → | Feb 8, 4:19 pm EST | Alfred P. SpadaEVP, R&D and CSO | 131,250 | — | — | 21,875 | — | |
| Feb 4, 2016 AForm 4 → | Feb 8, 4:18 pm EST | Steven J MentoPresident, CEO & Director, Director | 225,000 | — | — | 37,500 | — | |
| Jun 11, 2015 AForm 4 → | Jun 15, 4:12 pm EDT | Harold Van WartDirector | 15,000 | — | — | 15,000 | — | |
| Jun 11, 2015 AForm 4 → | Jun 15, 4:11 pm EDT | James Paul ScopaDirector | 15,000 | — | — | 15,000 | — | |
| Jun 11, 2015 AForm 4 → | Jun 15, 4:10 pm EDT | Shahzad MalikDirector, 10% Owner | 15,000 | — | — | 15,000 | — | |
| Jun 11, 2015 AForm 4 → | Jun 15, 4:09 pm EDT | Louis P LacasseDirector | 15,000 | — | — | 15,000 | — | |
| Jun 11, 2015 AForm 4 → | Jun 15, 4:08 pm EDT | Preston KlassenDirector | 15,000 | — | — | 15,000 | — | |
| Jun 11, 2015 AForm 4 → | Jun 15, 4:07 pm EDT | Daniel L KisnerDirector | 15,000 | — | — | 15,000 | — | |
| Jun 11, 2015 AForm 4 → | Jun 15, 4:06 pm EDT | David F HaleDirector | 35,000 | — | — | 35,000 | — | |
| Feb 23, 2015 AForm 4 → | Feb 25, 4:06 pm EST | Charles CashionSVP, Finance, CFO and Sec. | 50,000 | — | — | 50,000 | — | |
| Feb 23, 2015 AForm 4 → | Feb 25, 4:05 pm EST | Alfred P. SpadaEVP, R&D and CSO | 100,000 | — | — | 100,000 | — | |
| Feb 23, 2015 AForm 4 → | Feb 25, 4:04 pm EST | Steven J MentoPresident, CEO & Director, Director | 200,000 | — | — | 50,000 | — |